Cover Image

Osteosarcomatous Differentiation in Rebiopsy Specimens of Pulmonary Adenocarcinoma with EGFR-TKI Resistance

Saved in:

Bibliographic Details
Main Authors:	Hyein Ahn (Author), Hyun Jung Kwon (Author), Eunhyang Park (Author), Hyojin Kim (Author), Jin-Haeng Chung (Author)
Format:	Book
Published:	Korean Society of Pathologists & the Korean Society for Cytopathology, 2018-03-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Primary leiomyosarcoma with osteosarcomatous differentiation of the breast
by: Ekta Sethi, et al.
Published: (2024)

Landscape of EGFR mutations in lung adenocarcinoma: a single institute experience with comparison of PANAMutyper testing and targeted next-generation sequencing
by: Jeonghyo Lee, et al.
Published: (2022)

Chinese Herbal Medicine Combined With EGFR-TKI in EGFR Mutation-Positive Advanced Pulmonary Adenocarcinoma (CATLA): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
by: Lijing Jiao, et al.
Published: (2019)

Biomarker testing of cytology specimens in personalized medicine for lung cancer patients
by: Hyojin Kim, et al.
Published: (2022)

Breast Metaplastic Carcinoma With Osteosarcomatous Differentiation: A Case Report and literature Review
by: Xue Yang, et al.
Published: (2022)

Pre-treatment Neutrophil-to-Lymphocyte Ratio significantly affects progression free survival in positive EGFR mutation advanced lung adenocarcinoma with EGFR-TKI treatment in Bali, Indonesia
by: Widiasari Ni Putu Ayu, et al.
Published: (2023)

Aquaporin 1 Is an Independent Marker of Poor Prognosis in Lung Adenocarcinoma
by: Sumi Yun, et al.
Published: (2016)

Osteosarcomatous Divergence in Dedifferentiated Liposarcoma Presenting as a Colonic Mass
by: Jeenal Gordhandas, et al.
Published: (2019)

A case of Ph+ acute lymphoblastic leukemia and EGFR mutant lung adenocarcinoma synchronous overlap: may one TKI drug solve two diseases?
by: Qi Zhang, et al.
Published: (2024)

Furmonertinib for EGFR-mutant advanced non-small cell lung cancer: a glittering diamond in the rough of EGFR-TKI
by: Jianghua Ding, et al.
Published: (2024)

Human Leukocyte Antigen Class I and Programmed Death-Ligand 1 Coexpression Is an Independent Poor Prognostic Factor in Adenocarcinoma of the Lung
by: Yeon Bi Han, et al.
Published: (2019)

Deciphering the Dynamics of EGFR-TKI Resistance in Lung Cancer: Insights from Bibliometric Analysis
by: Zhou Y, et al.
Published: (2024)

Restricting Glutamine Uptake Enhances NSCLC Sensitivity to Third-Generation EGFR-TKI Almonertinib
by: Yaming Liu, et al.
Published: (2021)

Efficacy of immune checkpoint inhibitors in EGFR-Mutant NSCLC patients with EGFR-TKI resistance: A systematic review and meta-analysis
by: Xiaoyu Qian, et al.
Published: (2022)

The Multi-Omics Analysis of Key Genes Regulating EGFR-TKI Resistance, Immune Infiltration, SCLC Transformation in EGFR-Mutant NSCLC
by: Wang Z, et al.
Published: (2022)

Cytologic Characteristics of Thymic Adenocarcinoma with Enteric Differentiation: A Study of Four Fine-Needle Aspiration Specimens
by: Ah-Young Kwon, et al.
Published: (2017)

A case of concomitant EGFR/ALK alteration against a mutated EGFR background in early-stage lung adenocarcinoma
by: Ki-Chang Lee, et al.
Published: (2021)

Sarcomatoid Carcinoma of Renal Pelvis Involving Ureter and Renal Parenchyma with Heterologous Osteosarcomatous Differentiation: A Case Report and Review of Literature
by: Bhavya P.Mohan, et al.
Published: (2018)

Stevens-Johnson syndrome induced by toripalimab in a previously EGFR-TKI-treated advanced lung adenocarcinoma patient harboring EGFR mutations 19 del/T790M/C797S in trans and cis: a case report
by: Yang Chen, et al.
Published: (2023)

EGFR-mutated pulmonary adenocarcinoma with concurrent PIK3CA mutation, and with acquired RET fusion and EGFR T790M mutation after afatinib therapy
by: Minhye Kim, et al.
Published: (2021)

Targeting Nicotinamide N-Methyltransferase and miR-449a in EGFR-TKI-Resistant Non-Small-Cell Lung Cancer Cells
by: Duc-Hiep Bach, et al.
Published: (2018)

Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer in China
by: Yamin Shu, et al.
Published: (2022)

Membranous Insulin-like Growth Factor-1 Receptor (IGF1R) Expression Is Predictive of Poor Prognosis in Patients with Epidermal Growth Factor Receptor ()-Mutant Lung Adenocarcinoma
by: Eunhyang Park, et al.
Published: (2015)

Association of EGFR Tyrosine Kinase Inhibitor Treatment With Progression-Free Survival Among Taiwanese Patients With Advanced Lung Adenocarcinoma and EGFR Mutation
by: Po-Yen Chen, et al.
Published: (2021)

Chromosomal Copy Number Variation Predicts EGFR-TKI Response and Prognosis for Patients with Non-Small Cell Lung Cancer
by: He H, et al.
Published: (2023)

Paravertebral Well-Differentiated Liposarcoma with Low-Grade Osteosarcomatous Component: Case Report with 11-Year Follow-Up, Radiological, Pathological, and Genetic Data, and Literature Review
by: Nicolas Macagno, et al.
Published: (2017)

EGFR-gene analysis on cytological specimens of non-small-cell lung cancers
by: Feichter G, et al.
Published: (2007)

Case report: EGFR-TKI rechallenge after osimertinib-induced interstitial lung disease: a case report and literature review
by: Xiaofei Gu, et al.
Published: (2024)

Optimizing first-line TKI treatment efficacy in PD-L1-positive EGFR-mutated NSCLC: the impact of antiangiogenic agents
by: Xuanhong Jin, et al.
Published: (2024)

SH-1028, An Irreversible Third-Generation EGFR TKI, Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer
by: Luwei Han, et al.
Published: (2021)

Physiologically Based Pharmacokinetic (PBPK) Modeling to Predict PET Image Quality of Three Generations EGFR TKI in Advanced-Stage NSCLC Patients
by: I. H. Bartelink, et al.
Published: (2022)

Reproducibility determination of WHO classification of endometrial hyperplasia/well differentiated adenocarcinoma and comparison with computerized morphometric data in curettage specimens in Iran
by: Meysamie Ali, et al.
Published: (2009)

Clinicopathologic correlations of superficial esophageal adenocarcinoma in endoscopic submucosal dissection specimens
by: Sadhna Dhingra, et al.
Published: (2021)

Correction of acknowledgments: PD-L1 testing in non-small cell lung cancer: past, present, and future
by: Hyojin Kim, et al.
Published: (2020)

PD-L1 Testing in Non-small Cell Lung Cancer: Past, Present, and Future
by: Hyojin Kim, et al.
Published: (2019)

The TKI Era in Chronic Leukemias
by: Danilo De Novellis, et al.
Published: (2021)

Natural product manoalide promotes EGFR-TKI sensitivity of lung cancer cells by KRAS-ERK pathway and mitochondrial Ca2+ overload-induced ferroptosis
by: Yinyun Ni, et al.
Published: (2023)

Metformin Enhances TKI-Afatinib Cytotoxic Effect, Causing Downregulation of Glycolysis, Epithelial-Mesenchymal Transition, and EGFR-Signaling Pathway Activation in Lung Cancer Cells
by: Pedro Barrios-Bernal, et al.
Published: (2022)

The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study
by: Ping-Chih Hsu, et al.
Published: (2020)

Transformation to Small Cell Lung Cancer of Pulmonary Adenocarcinoma: Clinicopathologic Analysis of Six Cases
by: Soomin Ahn, et al.
Published: (2016)